Status:

UNKNOWN

A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis

Lead Sponsor:

Kansai Hepatobiliary Oncology Group

Conditions:

Biliary Tract Cancer

Eligibility:

All Genders

20+ years

Phase:

PHASE2

Brief Summary

To evaluate the efficacy and the safety of preoperative chemotherapy with Gemcitabine/ Cisplatin /S-1 for biliary tract cancers with lymph node metastasis by FDG-PET.

Detailed Description

Biliary tract cancer is one of the most lethal malignancies worldwide, with surgery representing the only potentially curative treatment for this disease. However, many patients are diagnosed as far a...

Eligibility Criteria

Inclusion

  • Patients with radiologically proven biliary tract cancer.
  • No extra-hepatic disease.
  • No prior therapy.
  • The function of the liver is kept as satisfied after hepatectomy.
  • No chronic liver damage.
  • Patients of age over 20 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Sufficient organ function (neutrophil count \>=1,500/mm3 and platelet count \>=100,000/mm3, Hemoglobin \>=9.0g/dL, Aspartate transaminase (AST)/alanine aminotransferase (ALT) \<=150 IU/L, total bilirubin \<=1.5 mg/dL , creatinine \<=1.2 mg/dL , creatinine clearance \>=60 mL/min) 9.Patients obtained written informed consent.

Exclusion

  • Massive abdominal effusion requiring treatment.
  • Active concomitant malignancy.
  • The case suspected of infection.
  • Patients with water solubility diarrhea.
  • Mental disease or psychotic manifestation.
  • Under continuous steroid therapy.
  • Patients with acute myocardial infarction.
  • Patients with severe complications.
  • Pregnancy or the desire to preserve fecundity.
  • Serious drug hypersensitivity or a history of drug allergy.
  • Any patients judged by the investigator to be unfit to participate in the study.

Key Trial Info

Start Date :

July 23 2013

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 1 2019

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT01821248

Start Date

July 23 2013

End Date

February 1 2019

Last Update

February 21 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Kyoto University Hospital

Kyoto, Japan, 606-8507